AlSharari et al. reported that the α9α10 nAChR antagonist RgIA was effective in an experimental colitis mice model and reduced the increased level of TNF-α, suggesting α9α10 nAChR as a potential target for inflammatory disorders [33]. This evidence concerns the gene TNF and colitis.